AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12793117
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (pharmacological therapy alone)
Trial: 15548314
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) 25 mg base/kg
Trial: 15548314
Drug: Sulfadoxine-pyrimethamine (SP)
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (SP) 1.25/25 mg/kg
Trial: 15548314
Drug: Mefloquine (M)
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefloquine (M) 15 mg base/kg
Trial: 15548314
Drug: Mefloquine-artesunate (MA)
RxNorm normalized name: artesunate and mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine-artesunate (MA) 15:4 mg/kg
Trial: 7833227
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg orally three times a day for 6 days followed by 7.5 mg zopiclone
Trial: 2901220
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg vs Ranitidine 300 mg
Trial: 2901220
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg vs Famotidine 40 mg
Trial: 28830555
Drug: Work-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work-focused cognitive behavioral therapy (6 sessions) and a small workplace intervention
Trial: 25297643
Drug: Prophylactic vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic vitamin K (single dose)
Trial: 21372622
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Group Therapy (CBGT) added to Treatment as Usual (TAU)
Trial: 18081756
Drug: Oral Language
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Language (OL) programme
Trial: 10833090
Drug: Pan+Amo+Cla (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pan+Amo+Cla (40 mg b.i.d. Pantoprazole, 1 g b.i.d. Amoxicillin, 500 mg b.i.d. Clarithromycin)
Trial: 10833090
Drug: RBC+Amo+Cla (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC+Amo+Cla (400 mg b.i.d. Ranitidine bismuth citrate, 1 g b.i.d. Amoxicillin, 500 mg b.i.d. Clarithromycin)
Trial: 7979074
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of bupivacaine 75 mg, clonidine 150 micrograms, and diamorphine 5 mg in 60 ml normal saline at 1-4 ml/h for 24-48 hours preoperatively and maintained for at least 3 days postoperatively
Trial: 7979074
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of bupivacaine, clonidine, and diamorphine
Trial: 776537
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg flupenthixol 2 to 4-times daily for 2 weeks
Trial: 776537
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo tablets 2 to 4-times daily for 2 weeks
Trial: 25040180
Drug: CLNP/BPO 3·0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLNP/BPO 3·0% twice daily
Trial: 25040180
Drug: CLNP/BPO 3·0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLNP/BPO 3·0% once daily
Trial: 23224626
Drug: Calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (500 mg/day) and vitamin D (60,000 IU/3 months)
Trial: 23224626
Drug: Calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (500 mg/day), vitamin D (60,000 IU/3 months), and zinc (as per Indian Recommended Allowance)
Trial: 11295650
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (200 microg twice daily for 6 weeks)
Trial: 7498360
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rhEpo) treatment; specific dosage and duration not mentioned.
Trial: 7498360
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group); 12 patients without PB CFU-E.
Trial: 7498360
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of PB CFU-E; no specific treatment mentioned.
Trial: 2023754
Drug: Pulse therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse therapy (prednisolone acetate 1% drops hourly and a single intravenous pulse of 500 mg methylprednisolone)
Trial: 2023754
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy (same topical therapy plus oral prednisone 60 to 80 mg daily)
Trial: 2023754
Drug: Pulse therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse therapy (for patients treated early, less than or equal to 8 days)
Trial: 2023754
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy (for patients treated early, less than or equal to 8 days)
Trial: 7032681
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum combined with radiation therapy (4 mg/m2 into tumor-bearing lymph nodes and 2, 2, 4, 4, and 4 mg/m2 intravenously at specified days)
Trial: 21289525
Drug: Bazedoxifene 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 5 mg
Trial: 21289525
Drug: Bazedoxifene 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 10 mg
Trial: 18777173
Drug: Topical miconazole
RxNorm normalized name: miconazole Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical miconazole oral gel (85 mg x 3, 3 days)
Trial: 18777173
Drug: Oral voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral voriconazole (400 mg x 2, 1st day, 200 mg x 2, 2nd day)
Trial: 17725472
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy plus exercise
Trial: 14747427
Drug: Aripiprazole 5
RxNorm normalized name: aripiprazole 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 5 mg, 10 mg, 15 mg, 20 mg once daily (Study 1)
Trial: 14747427
Drug: Aripiprazole titrated
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole titrated from 10 to 30 mg/day (Study 2)
Trial: 11393383
Drug: Isradipine 5
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5 mg daily
Trial: 11393383
Drug: Spirapril 3
RxNorm normalized name: spirapril 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril 3 mg and Isradipine 2.5 mg daily
Trial: 11393383
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Spirapril and Isradipine)
Trial: 332217
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg xipamid
Trial: 332217
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg xipamid
Trial: 31811128
Drug: Supervised high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised high-dose primaquine
Trial: 28941934
Drug: Nitrate supplementation
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate supplementation (140 ml of concentrated beetroot juice)
Trial: 1761065
Drug: Verapamil administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil administration
Trial: 15553660
Drug: Erdosteine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine (300 mg b.i.d. for 8 months)
Trial: 11761117
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group (168‐255 microg of each phthalate)
Trial: 11761117
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose group (336 to 510 microg of each phthalate)
Trial: 11761117
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dose)
Trial: 9247840
Drug: Cimetidine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1,000 mg daily over 20 days
Trial: 9247840
Drug: Cimetidine treatment
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine treatment with metamizol doses of 750 mg and 1,500 mg
Trial: 7506164
Drug: nimesulide (200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide (200mg twice daily)
Trial: 7506164
Drug: ketoprofen (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoprofen (100mg twice daily)
Trial: 2428719
Drug: Depot secretin
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depot secretin therapy (800 CU by subcutaneous injection twice daily for 7 days)
Trial: 26179237
Drug: Dacomitinib 45
RxNorm normalized name: dacomitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 45 mg alone under fasting conditions
Trial: 26179237
Drug: Dacomitinib 45
RxNorm normalized name: dacomitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 45 mg after a high-fat, high-calorie meal
Trial: 26179237
Drug: Dacomitinib 45
RxNorm normalized name: dacomitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 45 mg coadministered with rabeprazole 40 mg under fasting conditions
Trial: 19641362
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg once daily for 2 weeks
Trial: 17848492
Drug: Novel clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel clinical trial design (sequential parallel design)
Trial: 11406729
Drug: Warfarin 1
RxNorm normalized name: warfarin 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 1 mg
Trial: 11406729
Drug: Warfarin 2
RxNorm normalized name: warfarin 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 2 mg
Trial: 11406729
Drug: Warfarin 3
RxNorm normalized name: warfarin 3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 3 mg
Trial: 9720470
Drug: Cefaclor (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (40 mg/kg/day for 10 days)
Trial: 9720470
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (30 mg/kg/day for 10 days)
Trial: 3053887
Drug: Lactitol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactitol (10 g/6 h)
Trial: 3053887
Drug: Lactulose (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (15 ml/6 h, 66% w/v, containing 10 g of lactulose)
Trial: 7142087
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 500 mg cefadroxil
Trial: 7142087
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1 g cefadroxil
Trial: 7142087
Drug: Three repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three repeated doses of 500 mg cefadroxil
Trial: 7142087
Drug: Two repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two repeated doses of 1 g cefadroxil
Trial: 24799467
Drug: Control immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control immunotherapy (KLH plus GM-CSF)
Trial: 22691628
Drug: Masitinib (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masitinib (3 to 6 mg/kg/day for at least 12 months)
Trial: 17545861
Drug: Sublingual house
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual house dust-mite-specific immunotherapy for 2 years followed by 1 year of placebo (Group A)
Trial: 17545861
Drug: Sublingual house
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual house dust-mite-specific immunotherapy for 3 years (Group B)
Trial: 14991953
Drug: OAC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (omeprazole 20 mg + amoxicillin 1 000 mg + clarithromycin 250 mg)
Trial: 14991953
Drug: OFC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFC (omeprazole 20 mg + furazolidone 100 mg + clarithromycin 250 mg)
Trial: 14991953
Drug: OMC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC (omeprazole 20 mg + metronidazole 200 mg + clarithromycin 250 mg)
Trial: 14991953
Drug: OFA (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFA (omeprazole 20 mg + furazolidone 100 mg + amoxicillin 1 000 mg)
Trial: 28591155
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg orally twice daily for five days)
Trial: 25957214
Drug: Prophylaxis antibiotics
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis antibiotics
Trial: 24166282
Drug: Weekly ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly ixabepilone 16 mg/m2 as a 1-h IV infusion weekly on days 1, 8, and 15 of a 28-day cycle (1 week off therapy); n=85
Trial: 24166282
Drug: Every-3-week ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every-3-week ixabepilone 40 mg/m2 as a 3-h IV infusion on day 1 of a 21-day cycle; n=91
Trial: 21749265
Drug: Tilting Whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilting Whole Body Vibration therapy (WBV) for 12 weeks (12.5-Hz frequency; 3-mm amplitude)
Trial: 23370417
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg)
Trial: 17544776
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PDT with verteporfin and intravitreal bevacizumab
Trial: 15215482
Drug: Topical alpha-lactalbumin-oleic
RxNorm normalized name: alpha-lactalbumin (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical alpha-lactalbumin-oleic acid
Trial: 15215482
Drug: Topical alpha-lactalbumin-oleic
RxNorm normalized name: alpha-lactalbumin (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical alpha-lactalbumin-oleic acid (second phase)
Trial: 15215482
Drug: Topical alpha-lactalbumin-oleic
RxNorm normalized name: alpha-lactalbumin (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical alpha-lactalbumin-oleic acid (long-term follow-up)
Trial: 8090391
Drug: Prophylactic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic saline amnioinfusion (600‐mL bolus followed by 3 mL/minute)
Trial: 21474494
Drug: Individual music
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual music therapy plus standard care (20 bi‐weekly sessions)
Trial: 18284437
Drug: PF‐00734200 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐00734200 (0.3 to 300 mg)
Trial: 18284437
Drug: PF‐00734200 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐00734200 (10 mg)
Trial: 10839878
Drug: EMLA patch
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA patch (5%‐1 g)
Trial: 8401013
Drug: 15 mmol
RxNorm normalized name: dibasic potassium phosphate 15 MMOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mmol magnesium hydroxide daily for one year
Trial: 29376112
Drug: IVIG+ (Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG+ (Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy)
Trial: 29376112
Drug: NO-IVIG (No
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO-IVIG (No intravenous immunoglobulin with prednisone and risk-adapted chemotherapy)
Trial: 27250658
Drug: Sedation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation with a daily wake-up attempt
Trial: 22206777
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg reslizumab
Trial: 22206777
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg reslizumab
Trial: 22206777
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg reslizumab
Trial: 24980988
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg BIW
Trial: 15948997
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg BIW (after dose reduction from 50 mg)
Trial: 15948997
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg BIW (continuous)
Trial: 15948997
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by etanercept 25 mg BIW
Trial: 8902255
Drug: Cyclandelate (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate (1,200 mg daily for 12 weeks)
Trial: 8902255
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg daily for 12 weeks)
Trial: 27460541
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day for 12 weeks
Trial: 20370923
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of surgery and trocar techniques (Group B)
Trial: 17711710
Drug: Intravenous tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tirofiban bolus (10 microg/kg) prior to coronary angiography (Group IV)
Trial: 17711710
Drug: Intravenous tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tirofiban (Group IV)
Trial: 11432685
Drug: Ipsapirone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone (0.3 mg/kg)
Trial: 1334515
Drug: Zileuton (5-lipoxygenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton (5-lipoxygenase inhibitor)
Trial: 2165088
Drug: Clonidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (75 micrograms twice daily)
Trial: 2165088
Drug: Clonidine plus
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine plus chlorthalidone (15 mg)
Trial: 2165088
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chlorthalidone (15 mg)
Trial: 91439
Drug: Five-drug combination
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug combination chemotherapy program containing cis-dichlorodiammineplatinum(II)
Trial: 31421669
Drug: Individualized, tablet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized, tablet-based physiotherapy training programme
Trial: 16751033
Drug: 2 hours
RxNorm normalized name: PATCH, TRANSDERMAL 72 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hours of daily patching with 1 hour of near visual activities
Trial: 15289492
Drug: PC-SPES (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC-SPES (3 capsules orally three times a day)
Trial: 15289492
Drug: Diethylstilbestrol (DES,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES, 3 mg orally once a day)
Trial: 12451007
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of mineral water
Trial: 9720812
Drug: Immunotherapy against
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy against birch pollen
Trial: 17241499
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine infusion
Trial: 25137430
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline infusion